1-3 of 3
Neil James
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases

Available to Purchase
Alessia Anastasia, Giulia Dellavedova, Antonio Ramos-Montoya, Neil James, Giovanna Chiorino, Massimo Russo, Hana Baakza, Joanne Wilson, Carmen Ghilardi, Elaine B. Cadogan, Raffaella Giavazzi, Maria Rosa Bani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 555–567.
https://doi.org/10.1158/1535-7163.MCT-21-0420
Published: 01 April 2022
View article titled, The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases
Open the PDF for The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases in another window
Includes: Supplementary data
Journal Articles

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Free
Barry R. Davies, Nin Guan, Armelle Logie, Claire Crafter, Lyndsey Hanson, Vivien Jacobs, Neil James, Philippa Dudley, Kelly Jacques, Brendon Ladd, Celina M. D'Cruz, Michael Zinda, Justin Lindemann, Makoto Kodaira, Kenji Tamura, Emma L. Jenkins
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (11): 2441–2451.
https://doi.org/10.1158/1535-7163.MCT-15-0230
Published: 03 November 2015
View article titled, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
Open the PDF for Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract A13: Characterization of CRC primary explant models in comparison to standard human tumor cell-line-derived CRC xenografts.

Free
Denis G. Alferez, Helen Brown, Jonathan R. Dry, Sarah Runswick, Neil James, Gael McWalter, Jessica Whiteley, Mitch Revill, Garry Beran, Matthew Farren, Neil R. Smith, Phillip Hedge, Simon Barry, Stephen R. Wedge, Robert W. Wilkinson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A13.
https://doi.org/10.1158/1535-7163.TARG-11-A13
Published: 12 November 2011
View article titled, Abstract A13: Characterization of CRC primary explant models in comparison to standard human tumor cell-line-derived CRC xenografts.